Gefitinib

FDA Drug Profile — IRESSA, Gefitinib

Gefitinib is listed in the FDA National Drug Code directory with 12 NDC codes, marketed under brand names including IRESSA, Gefitinib. Available dosage forms: powder, tablet, coated, tablet, film coated.

Drug details

Generic Name
Gefitinib
Brand Names
IRESSA, Gefitinib
Application Number
NDA206995
Sponsor
Wisdom Pharmaceutical Co.,Ltd
NDC Codes
12
Dosage Forms
POWDER, TABLET, COATED, TABLET, FILM COATED
Routes
ORAL
Active Ingredients
GEFITINIB

Indications and Usage

1 INDICATIONS AND USAGE Gefitinib tablets are indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test [see Clinical Studies (14) ]. Limitation of Use: Safety and efficacy of gefitinib tablets have not been established in patients with metastatic NSCLC whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations [see Clinical Studies (14) ]. Gefitinib tablets are tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. ( 1 ) Limitation of Use: Safety and efficacy of gefitinib tablets have not been established in patients whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.